Jeavons Syndrome Clinical Trial
Official title:
An Open-Label Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of BMB-101 in Adolescents and Adults With Epilepsy With Eyelid Myoclonia (EEM; Jeavons Syndrome) Including Those With Prominent Photic Induction (Sunflower Syndrome)
The study is a pilot, open-label, study to test whether BMB-101 is safe and effective in reducing the frequency of seizures in subjects with Epilepsy with Eyelid Myoclonia (also called Jeavons Syndrome). The study will last up to 6 months. There will be a 1 month screening period, then 3 months on open-label BMB-101 including titration and tapering/washout periods, and then a 1 month follow-up period. There will be 7 clinic visits.
n/a